Barclays PLC Intellia Therapeutics, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $582,582 - $792,102	-29,100 Reduced 39.06%	45,400 $1.02 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $750,330 - $1.03 Million	31,500 Added 73.26%	74,500 $2.05 Million
Q4 2023 Feb 15, 2024	BUY	$23.16 - $32.34 $995,880 - $1.39 Million	43,000 New	43,000 $1.31 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $4.63 Million - $6.36 Million	-46,000 Reduced 87.29%	6,700 $793,000
Q3 2021 Nov 09, 2021	SELL	$132.37 - $176.78 $7.86 Million - $10.5 Million	-59,400 Reduced 52.99%	52,700 $7.07 Million
Q2 2021 Aug 13, 2021	BUY	$60.88 - $161.91 $182,640 - $485,730	3,000 Added 2.75%	112,100 $18.2 Million
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $5.08 Million - $9.13 Million	109,100 New	109,100 $8.76 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.